ACT and Catholic Healthcare West Sign Clinical Trial Agreement
Posted on: Thursday, 13 March 2008, 09:01 CDT
Advanced Cell Technology has signed a clinical trial agreement with Chandler Regional Medical Center and Mercy Gilbert Medical Center, members of Catholic Healthcare West, pursuant to which, they will become the company's clinical trial sites for the Phase II myoblast study.
In addition, Catholic Healthcare West (CHW) has received Institutional Review Board approval for the clinical trial, which is expected to begin soon. Advanced Cell Technology's (ACT) myoblast program is an autologous adult stem cell therapy for the treatment of heart disease that has successfully completed four Phase I clinical trials and received clearance from the FDA to begin Phase II trials.
William Caldwell, IV, chairman and CEO of ACT, said: "The agreement with CHW signifies our readiness to begin the Phase II clinical trial. We are excited to begin the trial, which has the potential to be a major advance for the field of regenerative medicine and, more importantly, to patients in need of care."
Source: Datamonitor
Related Articles
- AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
- Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
- Reportlinker Adds Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
- Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
- RhuDex(R) Achieves Positive Results in Clinical Phase IIa Trial
- Next Generation Nasal Spray Against Influenza: Clinical Phase I Study Started With FLUVACCdelNS1
- Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
- Biovitrum Wins Contract to Manufacture Pharmaceutical Substance For Resistentia's Clinical Phase III Trials of New Protein-Based Drug Candidate for the Treatment of Allergy
- Targeted Genetics Amends tgAAC94 Clinical Protocol and Advances Ongoing Trial to Phase I/II; Amendment Potentially Accelerates Clinical Development Of Therapy
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds